-
Je něco špatně v tomto záznamu ?
Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study
M. O'Loughlin, X. Andreu, S. Bianchi, E. Chemielik, A. Cordoba, G. Cserni, P. Figueiredo, G. Floris, MP. Foschini, P. Heikkilä, J. Kulka, I. Liepniece-Karele, P. Regitnig, A. Reiner, A. Ryska, A. Sapino, A. Shalaby, ES. Stovgaard, C. Quinn, EM....
Jazyk angličtina Země Nizozemsko
Typ dokumentu úvodníky, multicentrická studie
NLK
ProQuest Central
od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2005-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-01-01 do Před 1 rokem
Family Health Database (ProQuest)
od 1997-01-01 do Před 1 rokem
Public Health Database (ProQuest)
od 1997-01-01 do Před 1 rokem
- MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- nádorové biomarkery MeSH
- nádorové mikroprostředí MeSH
- neoadjuvantní terapie MeSH
- odchylka pozorovatele MeSH
- odds ratio MeSH
- prognóza MeSH
- reprodukovatelnost výsledků MeSH
- senioři MeSH
- staging nádorů MeSH
- stupeň nádoru MeSH
- triple-negativní karcinom prsu diagnóza imunologie terapie MeSH
- tumor infiltrující lymfocyty patologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- multicentrická studie MeSH
- úvodníky MeSH
BACKGROUND: Several studies have demonstrated a prognostic role for stromal tumour infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC). The reproducibility of scoring sTILs is variable with potentially excellent concordance being achievable using a software tool. We examined agreement between breast pathologists across Europe scoring sTILs on H&E-stained sections without software, an approach that is easily applied in clinical practice. The association between sTILs and response to anthracycline-taxane NACT was also examined. METHODOLOGY: Pathologists from the European Working Group for Breast Screening Pathology scored sTILs in 84 slides from 75 TNBCs using the immune-oncology biomarker working group guidance in two circulations. There were 16 participants in the first and 19 in the second circulation. RESULTS: Moderate agreement was achieved for absolute sTILs scores (intraclass correlation coefficient (ICC) = 0.683, 95% CI 0.601-0.767, p-value < 0.001). Agreement was less when a 25% threshold was used (ICC 0.509, 95% CI 0.416-0.614, p-value < 0.001) and for lymphocyte predominant breast cancer (LPBC) (ICC 0.504, 95% CI 0.412-0.610, p-value < 0.001). Intra-observer agreement was strong for absolute sTIL values (Spearman ρ = 0.727); fair for sTILs ≥ 25% (κ = 0.53) and for LPBC (κ = 0.49), but poor for sTILs as 10% increments (κ = 0.24). Increasing sTILs was significantly associated with an increased likelihood of a pathological complete response (pCR) on multivariable analysis. CONCLUSION: Increasing sTILs in TNBCs improves the likelihood of a pCR. However, inter-observer agreement is such that H&E-based assessment is not sufficiently reproducible for clinical application. Other methodologies should be explored, but may be at the cost of ease of application.
2nd Department of Pathology Semmelweis University Budapest Üllői út 93 1091 Budapest Hungary
Department of Pathology Charles University Medical Faculty Hospital Hradec Kralove Czech Republic
Department of Pathology Helsinki University Central Hospital Helsinki Finland
Department of Pathology Rion University Hospital University of Patras Medical School Patras Greece
Department of Pathology University Hospitals Leuven Leuven Belgium
Dip di Scienze Mediche Candiolo Cancer Institute FPO IRCCS Università di Torino Turin Italy
Discipline of Pathology National University of Ireland Galway Ireland
Institute of Pathology Danube Hospital Langobardenstrasse 122 1220 Vienna Austria
Lab Histopatologia Av Bissaya Barreto Apartado 2005 3001 651 Coimbra Portugal
Medizinische Universität Graz Institut für Pathologie Graz Austria
Pathology Centre Riga East Clinical University Hospital Riga Latvia
Pathology Department Herlev University Hospital Herlev Denmark
Tumor Pathology Department Maria Sklodowska Curie Institute Oncology Center Gliwice Poland
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19012660
- 003
- CZ-PrNML
- 005
- 20190411093806.0
- 007
- ta
- 008
- 190405s2018 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s10549-018-4825-8 $2 doi
- 035 __
- $a (PubMed)29774470
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a O'Loughlin, Mark $u Discipline of Pathology, National University of Ireland, Galway, Ireland.
- 245 10
- $a Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study / $c M. O'Loughlin, X. Andreu, S. Bianchi, E. Chemielik, A. Cordoba, G. Cserni, P. Figueiredo, G. Floris, MP. Foschini, P. Heikkilä, J. Kulka, I. Liepniece-Karele, P. Regitnig, A. Reiner, A. Ryska, A. Sapino, A. Shalaby, ES. Stovgaard, C. Quinn, EM. Walsh, V. Zolota, SA. Glynn, G. Callagy,
- 520 9_
- $a BACKGROUND: Several studies have demonstrated a prognostic role for stromal tumour infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC). The reproducibility of scoring sTILs is variable with potentially excellent concordance being achievable using a software tool. We examined agreement between breast pathologists across Europe scoring sTILs on H&E-stained sections without software, an approach that is easily applied in clinical practice. The association between sTILs and response to anthracycline-taxane NACT was also examined. METHODOLOGY: Pathologists from the European Working Group for Breast Screening Pathology scored sTILs in 84 slides from 75 TNBCs using the immune-oncology biomarker working group guidance in two circulations. There were 16 participants in the first and 19 in the second circulation. RESULTS: Moderate agreement was achieved for absolute sTILs scores (intraclass correlation coefficient (ICC) = 0.683, 95% CI 0.601-0.767, p-value < 0.001). Agreement was less when a 25% threshold was used (ICC 0.509, 95% CI 0.416-0.614, p-value < 0.001) and for lymphocyte predominant breast cancer (LPBC) (ICC 0.504, 95% CI 0.412-0.610, p-value < 0.001). Intra-observer agreement was strong for absolute sTIL values (Spearman ρ = 0.727); fair for sTILs ≥ 25% (κ = 0.53) and for LPBC (κ = 0.49), but poor for sTILs as 10% increments (κ = 0.24). Increasing sTILs was significantly associated with an increased likelihood of a pathological complete response (pCR) on multivariable analysis. CONCLUSION: Increasing sTILs in TNBCs improves the likelihood of a pCR. However, inter-observer agreement is such that H&E-based assessment is not sufficiently reproducible for clinical application. Other methodologies should be explored, but may be at the cost of ease of application.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a nádorové biomarkery $7 D014408
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a tumor infiltrující lymfocyty $x patologie $7 D016246
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a neoadjuvantní terapie $7 D020360
- 650 _2
- $a stupeň nádoru $7 D060787
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a odchylka pozorovatele $7 D015588
- 650 _2
- $a odds ratio $7 D016017
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a reprodukovatelnost výsledků $7 D015203
- 650 _2
- $a triple-negativní karcinom prsu $x diagnóza $x imunologie $x terapie $7 D064726
- 650 _2
- $a nádorové mikroprostředí $7 D059016
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a úvodníky $7 D016421
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Andreu, Xavier $u Pathology Department, UDIAT, Centre Diagnostic, Corporacio Sanitaria del Parc Taulí-Institut Universitari Parc Taulí-UAB, Sabadell, Spain.
- 700 1_
- $a Bianchi, Simonetta $u Department of Surgery and Translational Medicine, AOU Careggi, University of Florence, Largo G. Brambilla 3, 50134, Florence, Italy.
- 700 1_
- $a Chemielik, Ewa $u Tumor Pathology Department, Maria Sklodowska-Curie Institute-Oncology Center, Gliwice, Poland.
- 700 1_
- $a Cordoba, Alicia $u Department of Pathology Section A, Navarra Health Service, Hospital Complex of Navarra, Irunlarrea 4, 31008, Pamplona, Spain.
- 700 1_
- $a Cserni, Gábor $u Department of Pathology, Bács-Kiskun County Teaching Hospital, Nyiri ut 38., 6000, Kecskemét, Hungary. Department of Pathology, University of Szeged, Állomás u. 1, 6725, Szeged, Hungary.
- 700 1_
- $a Figueiredo, Paulo $u Lab Histopatologia, Av Bissaya Barreto, Apartado 2005, 3001-651, Coimbra, Portugal.
- 700 1_
- $a Floris, Giuseppe $u Department of Pathology, University Hospitals Leuven, Leuven, Belgium.
- 700 1_
- $a Foschini, Maria P $u Department of Biomedical and Neuromotor Sciences, Section of Anatomic Pathology University of Bologna, Ospedale Bellaria Via Altura 3, 40139, Bologna, Italy.
- 700 1_
- $a Heikkilä, Päivi $u Department of Pathology, Helsinki University Central Hospital, Helsinki, Finland.
- 700 1_
- $a Kulka, Janina $u 2nd Department of Pathology, Semmelweis University Budapest, Üllői út 93, 1091, Budapest, Hungary.
- 700 1_
- $a Liepniece-Karele, Inta $u Pathology Centre, Riga East Clinical University Hospital, Riga, Latvia.
- 700 1_
- $a Regitnig, Peter $u Medizinische Universität Graz, Institut für Pathologie, Graz, Austria.
- 700 1_
- $a Reiner, Angelika $u Institute of Pathology, Danube Hospital, Langobardenstrasse 122, 1220, Vienna, Austria.
- 700 1_
- $a Ryska, Ales $u Department of Pathology, Charles University Medical Faculty Hospital, Hradec Kralove, Czech Republic.
- 700 1_
- $a Sapino, Anna $u Dip. di Scienze Mediche, Candiolo Cancer Institute - FPO, IRCCS, Università di Torino, Turin, Italy.
- 700 1_
- $a Shalaby, Aliaa $u Discipline of Pathology, National University of Ireland, Galway, Ireland.
- 700 1_
- $a Stovgaard, Elisabeth Specht $u Pathology Department, Herlev University Hospital, Herlev, Denmark.
- 700 1_
- $a Quinn, Cecily $u Irish National Breast Screening Programme, BreastCheck, Dublin, Ireland. School of Medicine, University College Dublin, Dublin, Ireland.
- 700 1_
- $a Walsh, Elaine M $u Discipline of Pathology, National University of Ireland, Galway, Ireland.
- 700 1_
- $a Zolota, Vicky $u Department of Pathology, Rion University Hospital, University of Patras, Medical School, Patras, Greece.
- 700 1_
- $a Glynn, Sharon A $u Discipline of Pathology, National University of Ireland, Galway, Ireland.
- 700 1_
- $a Callagy, Grace $u Discipline of Pathology, National University of Ireland, Galway, Ireland. grace.callagy@nuigalway.ie. Division of Anatomic Pathology, Galway University Hospital, Newcastle Road, Galway, Ireland. grace.callagy@nuigalway.ie.
- 773 0_
- $w MED00009361 $t Breast cancer research and treatment $x 1573-7217 $g Roč. 171, č. 1 (2018), s. 1-9
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29774470 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190411093823 $b ABA008
- 999 __
- $a ok $b bmc $g 1391970 $s 1050965
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 171 $c 1 $d 1-9 $e 20180517 $i 1573-7217 $m Breast cancer research and treatment $n Breast Cancer Res Treat $x MED00009361
- LZP __
- $a Pubmed-20190405
